Department of Dermatology, AP-HP, Henri Mondor Hospital, FR-94000 Créteil, France.
Dermatology. 2013;226(1):15-8. doi: 10.1159/000346242. Epub 2013 Jan 22.
Human immunodeficiency virus (HIV)-related CD8+ cutaneous pseudolymphoma (CD8+ cytotoxic T cell skin infiltrative disease) is an inflammatory process resulting from a massive infiltration of the skin by activated, oligoclonal, HIV-specific, cytotoxic T lymphocytes. Usually, CD8+ cutaneous pseudolymphoma affects patients with a deep immunosuppression, and is rare in patients with mild immunosuppression. In deeply immunocompromised patients, highly active antiretroviral therapy (HAART) is considered as the first-line treatment. In contrast, the choice of therapy in moderately immunocompromised patients and/or patients already receiving HAART remains nonconsensual. We report a case of HIV-related CD8+ cutaneous pseudolymphoma in a moderately immunocompromised patient who was successfully and safely treated with methotrexate. We review the literature on HIV-related CD8+ pseudolymphoma and the use of methotrexate in HIV-positive patients.
人类免疫缺陷病毒（HIV）相关的 CD8+ 皮肤假淋巴瘤（CD8+ 细胞毒性 T 细胞皮肤浸润性疾病）是一种炎症过程，由大量激活的、寡克隆的、HIV 特异性的、细胞毒性 T 淋巴细胞浸润皮肤引起。通常，CD8+皮肤假淋巴瘤影响深度免疫抑制的患者，而在轻度免疫抑制的患者中很少见。在深度免疫抑制的患者中，高效抗逆转录病毒治疗（HAART）被认为是一线治疗方法。相比之下，中度免疫抑制的患者和/或已经接受 HAART 的患者的治疗选择仍然存在争议。我们报告了一例中度免疫抑制的 HIV 相关 CD8+ 皮肤假淋巴瘤患者，该患者成功且安全地接受了甲氨蝶呤治疗。我们回顾了 HIV 相关 CD8+ 假淋巴瘤的文献以及甲氨蝶呤在 HIV 阳性患者中的应用。
